These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 20589368

  • 1. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
    Lee S, Glendenning P, Inderjeeth CA.
    Osteoporos Int; 2011 Mar; 22(3):741-53. PubMed ID: 20589368
    [Abstract] [Full Text] [Related]

  • 2. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States.
    Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R.
    Arch Osteoporos; 2017 Dec; 12(1):22. PubMed ID: 28243883
    [Abstract] [Full Text] [Related]

  • 3. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA, Amonkar MM, Hebborn A, Altman R.
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [Abstract] [Full Text] [Related]

  • 4. Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.
    Rackoff PJ, Sebba A.
    Treat Endocrinol; 2005 Sep; 4(4):245-51. PubMed ID: 16053341
    [Abstract] [Full Text] [Related]

  • 5. Adherence to osteoporosis medications amongst Singaporean patients.
    Cheen MH, Kong MC, Zhang RF, Tee FM, Chandran M.
    Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
    [Abstract] [Full Text] [Related]

  • 6. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.
    Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C.
    Osteoporos Int; 2010 Jan; 21(1):145-55. PubMed ID: 19459025
    [Abstract] [Full Text] [Related]

  • 7. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.
    Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY.
    Osteoporos Int; 2008 Jun; 19(6):811-8. PubMed ID: 17999022
    [Abstract] [Full Text] [Related]

  • 8. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
    Gold DT, Safi W, Trinh H.
    Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
    [Abstract] [Full Text] [Related]

  • 9. Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.
    Sahota O, Narayanasamy M, Bastounis A, Paskins Z, Bishop S, Langley T, Gittoes N, Davis S, Baily A, Holmes M, Leonardi-Bee J.
    Health Technol Assess; 2024 Apr; 28(21):1-169. PubMed ID: 38634483
    [Abstract] [Full Text] [Related]

  • 10. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
    Bobba RS, Beattie K, Parkinson B, Kumbhare D, Adachi JD.
    Drug Saf; 2006 Apr; 29(12):1133-52. PubMed ID: 17147460
    [Abstract] [Full Text] [Related]

  • 11. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.
    Penning-van Beest FJ, Erkens JA, Olson M, Herings RM.
    Curr Med Res Opin; 2008 May; 24(5):1337-44. PubMed ID: 18380910
    [Abstract] [Full Text] [Related]

  • 12. Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
    Chung YS, Lim SK, Chung HY, Lee IK, Park IH, Kim GS, Min YK, Kang MI, Chung DJ, Kim YK, Choi WH, Shong MH, Park JH, Byun DW, Yoon HK, Shin CS, Lee YS, Kwon NH.
    Calcif Tissue Int; 2009 Nov; 85(5):389-97. PubMed ID: 19816648
    [Abstract] [Full Text] [Related]

  • 13. Differences in persistence among different weekly oral bisphosphonate medications.
    Sheehy O, Kindundu CM, Barbeau M, LeLorier J.
    Osteoporos Int; 2009 Aug; 20(8):1369-76. PubMed ID: 19020921
    [Abstract] [Full Text] [Related]

  • 14. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
    Hadji P, Felsenberg D, Amling M, Hofbauer LC, Kandenwein JA, Kurth A.
    Osteoporos Int; 2014 Jan; 25(1):339-47. PubMed ID: 24091594
    [Abstract] [Full Text] [Related]

  • 15. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J.
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term experience with alendronate in the treatment of osteoporosis.
    Hochberg MC, Rizzoli R.
    Expert Opin Pharmacother; 2006 Jun; 7(9):1201-10. PubMed ID: 16732706
    [Abstract] [Full Text] [Related]

  • 18. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F, Borges JL, Curiel MD.
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [Abstract] [Full Text] [Related]

  • 19. [Postmenopausal osteoporosis. Bisphosphonates are not all equal].
    MMW Fortschr Med; 2009 Mar 12; 151(11):46-7. PubMed ID: 19469206
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.